Abstract
Squamous cell carcinoma (SCC) is an invasive malignancy of epidermal keratinocytes. Surgical excision is currently the main treatment; however, this can cause scarring and disfigurement. There is accordingly, an acute need for alternative strategies to treat SCC. The transcription factor c-Jun is expressed in human SCC and another common form of invasive skin cancer, basal cell carcinoma together with the mitogenic marker-proliferating cell nuclear antigen. Here, we have employed DNAzymes (catalytic DNA molecules) targeting c-Jun (Dz13) to inhibit c-Jun expression in SCC cells. Dz13 inhibits SCC proliferation and suppresses solid SCC tumor growth and tumor angiogenesis in severe combined immunodeficient mice. We further demonstrate that Dz13 inhibits c-Jun, together with matrix metalloproteinase (MMP)-2 and MMP-9 expression in the tumors, consistent with DNAzyme inhibition of MMP-2 and MMP-9 gelatinolytic activity by zymography. Dz13 also suppressed the expression of vascular endothelial growth factor and fibroblast growth factor-2 in the tumors. These findings demonstrate that c-Jun regulates SCC growth and suggest that DNAzymes targeting this transcription factor may potentially be useful as inhibitors of cutaneous carcinoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agar NS, Halliday GM, Barnetson RS, Anathaswamy HN, Wheeler M, Jones AM . (2004). Proc Natl Acad Sci USA 101: 4954–4959.
Bernstein SC, Lim KK, Brodland DG, Heidelberg KA . (1996). Dermatol Surg 22: 243–254.
Bowden GT, Schneider B, Domann R, Kulesz-Martin M . (1994). Cancer Res 54: 1882s–1885s.
Ciardella AP, Donsoff IM, Guyer DR, Adamis A, Yannuzzi LA . (2002). Ophthalmol Clin North Am 15: 453–458.
Dass CR, Saravolac EG, Li Y, Sun LQ . (2002). Antisense Nucleic Acid Drug Dev 12: 289–299.
Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM . (2003). Nat Med 9: 1026–1032.
Ferrara N . (2002). Semin Oncol 29: 10–14.
Folkman J . (1972). Ann Surg 175: 409–416.
Fuchs S, Kornowski R, Leon MB, Epstein SE . (2001). Int J Cardiovasc Intervent 4: 3–6.
Halliday GM, Le S . (2001). Int Immunol 13: 1147–1154.
Hanahan D, Folkman J . (1996). Cell 86: 353–364.
Herbst RS, Kim ES, Harari PM . (2001). Expert Opin Biol Ther 1: 719–732.
Hilberg F, Aguzzi A, Howells N, Wagner EF . (1993). Nature 365: 179–181.
Johnson RS, van Lingen B, Papaioannou VE, Spiegelman BM . (1993). Genes Dev 7: 1309–1317.
Johnson TM, Rowe DE, Nelson BR, Swanson NA . (1992). J Am Acad Dermatol 26: 467–484.
Karamouzis MV, Sotiropoulou-Bonikou G, Vandoros G, Varakis I, Papavassiliou AG . (2004). Eur J Cancer 40: 761–773.
Kerbel R, Folkman J . (2002). Nat Rev Cancer 2: 727–739.
Kerkela E, Saarialho-Kere U . (2003). Exp Dermatol 12: 109–125.
Khachigian LM . (2000). J Clin Invest 106: 1189–1195.
Khachigian LM . (2002). Curr Opin Mol Ther 4: 119–121.
Kovary K, Bravo R . (1991). Mol Cell Biol 11: 4466–4472.
Kraus S, Miller BH, Swinehart JM, Shavin JS, Georgouras KE, Jenner DA et al. (1998). J Am Acad Dermatol 38: 438–442.
Lowe HC, Chesterman CN, Khachigian LM . (2002). Thromb Haemost 87: 134–140.
Lowe HC, Fahmy RG, Kavurma MM, Baker A, Chesterman CN, Khachigian LM . (2001). Circ Res 89: 670–677.
Malliri A, Symons M, Hennigan RF, Hurlstone AF, Lamb RF, Wheeler T et al. (1998). J Cell Biol 143: 1087–1099.
Patel BP, Shah PM, Rawal UM, Desai AA, Shah SV, Rawal RM et al. (2005). J Surg Oncol 90: 81–88.
Ro YS . (1995). J Korean Med Sci 10: 85–92.
Santiago FS, Lowe HC, Kavurma MM, Chesterman CN, Baker A, Atkins DG et al. (1999). Nat Med 5: 1264–1269.
Santoro SW, Joyce GF . (1997). Proc Natl Acad Sci USA 94: 4262–4266.
Sato H, Suzuki JS, Tanaka M, Ogiso M, Tohyama C, Kobayashi S . (1997). Photochem Photobiol 65: 908–914.
Schubert S, Gul DC, Grunert HP, Zeichhardt H, Erdmann VA, Kurreck J . (2003). Nucleic Acids Res 31: 5982–5992.
Shaulian E, Karin M . (2001). Oncogene 20: 2390–2400.
Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M . (2000). Cell 103: 897–907.
Shin M, Yan C, Boyd D . (2002). Biochim Biophys Acta 1589: 311–316.
Young MR, Li JJ, Rincon M, Flavell RA, Sathyanarayana BK, Hunziker R et al. (1999). Proc Natl Acad Sci USA 96: 9827–9832.
Zhang G, Dass CR, Sumithran E, Di Girolimo NR, Sun L-Q, Khachigian LM . (2004). J Natl Cancer Inst 96: 683–696.
Acknowledgements
This work was supported by grants from the NSW Cancer Council and National Health and Medical Research Council of Australia. LMK is a Senior Principal Research Fellow of the NHMRC.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, G., Luo, X., Sumithran, E. et al. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 25, 7260–7266 (2006). https://doi.org/10.1038/sj.onc.1209726
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209726
Keywords
This article is cited by
-
Melanoma protective antitumor immunity activated by catalytic DNA
Oncogene (2018)
-
Therapeutic potential of siRNA and DNAzymes in cancer
Tumor Biology (2014)
-
Use of DNAzymes for cancer research and therapy
Chinese Science Bulletin (2012)
-
c-Jun Promotes whereas JunB Inhibits Epidermal Neoplasia
Journal of Investigative Dermatology (2011)
-
Emerging therapeutic approaches in the management of retinal angiogenesis and edema
Journal of Molecular Medicine (2011)